Cerevance Appoints Sagar Vaidya, M.D. Ph.D., as Chief Medical Officer
August 12, 2024 08:30 ET
|
Cerevance
BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Cerevance, a leading clinical-stage biopharmaceutical company focused on developing precision novel therapeutics for central nervous system (CNS) diseases,...
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
June 18, 2024 08:30 ET
|
Cerevance
BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will deliver a poster presentation at the...
Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
May 20, 2024 08:00 ET
|
Cerevance
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief...
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
May 09, 2024 08:00 ET
|
Cerevance
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will present an oral presentation at the...
Cerevance Achieves First Milestone in Research Collaboration with Merck
May 02, 2024 08:30 ET
|
Cerevance
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced the achievement of the first...
Cerevance to Participate at Upcoming Investor Conferences
April 29, 2024 08:30 ET
|
Cerevance
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that company management will...
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
April 25, 2024 08:00 ET
|
Cerevance
Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others Proceeds will advance Cerevance’s first-in-class...
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
April 22, 2024 08:30 ET
|
Cerevance
BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that the peer-reviewed...
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
April 17, 2024 08:30 ET
|
Cerevance
BOSTON, April 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to deliver an oral...
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
April 02, 2024 08:30 ET
|
Cerevance
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the...